

Valaciclovir

【OVALT】 Valtrex<sup>®</sup> 500mg/Tab

ATC Code : J05AB11

中文名： 祛疹易錠 «GSK»

適應症： 帶狀皰疹、復發性生殖器皰疹。

藥理分類： **Antiviral Agent, Oral.**

用法用量： There are no data available on the use of Valtrex<sup>®</sup> in children.

**Administration:** Orally, taken with or without food, if GI upset occurs, administer with meals.

**Indications and dosage regimens:**

**Herpes Zoster:**

- 1 g TID for 7 days
- Initiate therapy at earliest sign or symptom (preferably within 48 hrs of rash onset); efficacy not established if initiated > 72 hrs after rash onset.

**Mucocutaneous Herpes Simplex Virus (HSV) Infections:**

- 500 mg BID for chronic suppressive or maintenance therapy (secondary prophylaxis) of HSV infections in HIV-infected adults who have frequent or severe recurrences.

**Herpes Labialis:**

- 2 g every 12 hours for 1 day; treatment for cold sores should not exceed 1 day.
- Initiate treatment at earliest symptom of cold sore (e.g., tingling, itching, burning); efficacy not established if initiated after development of clinical signs of cold sore (e.g., papule, vesicle, ulcer).

**Genital Herpes:**

- Treatment of **Initial Episodes:** 1g BID for 7-10 days  
For initial episodes treatment should be extended to 10 days.
- Episodic Treatment of **Recurrent Episodes:**  
500 mg BID for 3-5 days. Alternatively, 1g QD for 5 days.
- Chronic Suppression of Recurrent Episodes:  
1 g QD in immunocompetent adults. Alternatively, 500 mg QD for those with a history of 9 recurrences per year.
- Reduction of Transmission:  
500 mg QD in source partner with a history of 9 recurrences per year.

**Dosage in Patients with Renal Impairment:**

Table 1

Clcr(mL/min)	Daily Dosage	
	Herpes Labialis	Herpes Zoster
> 50	2 g Q12h for 1 day	1 g Q8h
30-49	1 g Q12h for 1 day	1 g Q12h
10-29	0.5 g Q12h for 1 day	1 g Q24h
< 10	A single dose for 1 day	0.5 g Q24h

Table 2-1. Dosage for Treatment of Genital Herpes in Renal Impairment

Clcr(mL/min)	Daily Dosage	
	Initial Episode	Episodic Treatment of Recurrent Episodes
> 50	1 g Q12h	0.5 g Q12h
30-49	1 g Q12h	0.5 g Q12h
10-29	1 g Q24h	0.5 g Q24h
< 10	0.5 g Q24h	0.5 g Q24h

Table 2-2. Dosage for Treatment of Genital Herpes in Renal Impairment

Clcr(mL/min)	Suppressive Therapy of Recurrent Episodes		
	Immunocompetent with		HIV-infected individuals
	> 9 Episodes/yr	< 9 Episodes/yr	
> 50	1 g Q24h	0.5 g Q24h	0.5 g Q12h
30-49	1 g Q24h	0.5 g Q24h	0.5 g Q12h
10-29	0.5 g Q24h	0.5 g Q48h	0.5 g Q24h
< 10	0.5 g Q24h	0.5 g Q48h	0.5 g Q24h

— Hemodialysis: Usual dose should be administered after hemodialysis.

— Peritoneal dialysis: Supplemental doses unnecessary following CAPD or CAVHD.

**不良反應：** 頭痛、噁心、嘔吐。長期高劑量使用本劑，曾發生腎功能不全、小血管病變性溶血性貧血、血小板過低症。

**交互作用：**

- Valaciclovir may increase the serum level of **TiZANidine**.
- Valaciclovir ↑ the serum level of **Mycophenolate**. Mycophenolate may ↑ the serum concentration of Valacyclovir.
- Valacyclovir may ↑ the serum level of **Tenofovir** Products. Tenofovir Products may ↑ the serum concentration of Valacyclovir.
- Valacyclovir ( a CYP1A2 Inhibitors) may ↑ the serum level of **Theophylline** Derivatives.

**注意事項：** 嚴重腎功能損傷方須調整劑量。

**懷 孕 期：** 相關安全資料有限，只有在益處大於可能風險時才使用。

**授 乳 期：** 小心使用。Valaciclovir 在體內會快速且幾乎完全代謝成 acyclovir、amino acid 及 L-valine，其中 acyclovir 有 30-40% 會集中在乳汁。由於 acyclovir 並無授乳期間之不良反應報告，臨床上並可用來治療新生兒皰疹病毒感染，因此，美國小兒科醫學會認為 acyclovir 可用於授乳婦， Valaciclovir 亦可於授乳期使用。

**使用規定：** 全民健保藥品給付規定：

1. 使用本類製劑應以下列條件為限：(1)帶狀疱疹或單純性疱疹侵犯三叉神經第一分枝 VI 皮節，可能危及眼角膜者。(2)帶狀疱疹或單純性疱疹侵犯薦椎 S2 皮節，將影響排泄功能者。(3)免疫機能不全、癌症、器官移植等病患之感染帶狀疱疹或單純性疱疹者。(4)帶狀疱疹或單純性疱疹所引起之角膜炎或角膜潰瘍者。(5)急性視網膜壞死症 (acute retina necrosis)。(6)帶狀疱疹發疹 3

日內且感染部位在頭頸部、生殖器周圍之病人，可給予5日內之口服或外用藥品。(7)骨髓移植術後病患得依下列規定用於預防復發性生殖器疱疹：A.限接受異體骨髓移植病患。B.接受高劑量化療或全身放射治療(TBI)前一天至移植術後第30天為止。

2. Acyclovir、famciclovir 及 valaciclovir 除上述特別規定外，使用療程原則以10天為限，口服、注射劑及外用藥膏擇一使用，不得合併使用。